Actualités

Merck (NYSE:MRK) said the FDA and EMA have accepted supplemental applications to expand ENFLONSIA for preventing RSV in young children at elevated risk. The filings seek to broaden ENFLONSIA's indication in vulnerable pediatric groups where preventative options for RSV are limited. The dual U.S. and European regulatory milestones highlight Merck's efforts to build out its portfolio beyond oncology as attention on the future of Keytruda intensifies. For investors tracking how large drug...

Eli Lilly just posted its fourth straight earnings beat and raised guidance again, but the real question is whether a next-generation obesity drug still sitting below Wall Street's radar could push the stock well past current targets.

Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.

Bristol Myers Squibb's Growth Portfolio and pipeline support momentum, but generic headwinds and recent gains call for a cautious stance.

Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues and prompting a review of full-year guidance.

GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and pipeline progress support momentum.

Merck beat Q2 earnings and sales estimates as strong oncology and newer products lift results, prompting the company to raise and narrow its 2026 sales outlook.

Moderna’s vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.

All three major US stock indexes were up in late-morning trading Tuesday, as investors grew more opt

Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both ph

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

Merck (MRK) delivered earnings and revenue surprises of +50.00% and +1.69%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Investing.com -- Merck reported significantly better-than-expected earnings for the second quarter, while narrowing and raising its full-year revenue outlook.

(Updates with market moves at the end of the day, and other changes, if any.) The Dow Jones Indus

Stock Market Today: The Dow Jones index rallied 600 points Monday after Trump called off new U.S. strikes on Iran. Oil prices plunged.

Eli Lilly stock ran on a story that was public and dated long before the price moved, and reading it right still would not have put you ahead of every peer.

Moderna posted a narrower per-share loss and higher revenue in its latest quarter, but shares were tumbling anyway. Moderna posted a loss of $1.97 a share, narrower than the loss of $2.01 Wall Street had anticipated, and slimmer than the per-share loss of $2.13 reported last year. The drugmaker reiterated its full-year guidance of 10% revenue growth, evenly split between U.S. and international sales.

Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved.

AbbVie's two newest drugs are growing so fast they've rewritten the company's entire story, and Wall Street may not have fully priced in what happens when the July 31 earnings report confirms it.

Merck (NYSE:MRK) reported that KEYTRUDA met its primary endpoint of progression free survival in the Phase 3 KEYNOTE C93 trial for advanced or recurrent endometrial cancer. The company highlighted this as the first time a PD 1 inhibitor has shown a statistically significant benefit over platinum chemotherapy in this patient population. The data are described as a high impact development for Merck's oncology portfolio, with potential implications for future regulatory filings. For investors...

AstraZeneca tops Q2 earnings and revenue estimates as strong demand for oncology and rare disease drugs helps offset growing generic competition across key products.

Applying the Dogs of the Dow logic across the entire S&P 500 sounds like a recipe for chasing troubled dividends, but a holding-by-holding look at SDOG reveals a more complicated picture, with two positions that deserve serious scrutiny before you commit capital.

Big Pharma is buying its way out of the patent cliff, while Novartis AG (NYSE:NVS) is trying to out-develop it. A Record Year for Biotech Deals The scale of that buying activity appears in this year’s deal totals. Biotech M&A has hit a record pace in 2026, with deal value reaching $216 billion so far […]

Merck (NYSE:MRK) received FDA approval for Lipfendra (enlicitide), the first oral PCSK9 cholesterol-lowering drug. Lipfendra introduces an oral option for patients who have so far relied on injectable PCSK9 therapies. The approval expands Merck’s presence in cardiovascular medicine as key products approach patent expirations. Merck, trading around $127.5, is adding Lipfendra to its portfolio at a time when NYSE:MRK has posted a 64.8% return over the past year and 92.2% over five years. The...

Merck shares climb after the FDA approved Lipfendra, the first oral PCSK9 inhibitor for lowering LDL cholesterol, with the launch expected in weeks.

MSD has outpaced rivals to market the first PCSK9 inhibitor in pill form for patients with high cholesterol.

Merck snagged the first-ever approval for a PCSK9 pill to lower LDL cholesterol, starting a new rivalry with injection-makers.

The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former commissioner Marty Makary.

Johnson and Johnson has quietly become one of the best-performing mega-caps of the past year, but with a fresh pullback and a pipeline firing on multiple cylinders, the bigger question is whether the next leg higher finally breaks through to record territory.

Merck (NYSE:MRK) received FDA approval for expanded use of Keytruda and Keytruda QLEX combinations with Padcev in muscle-invasive bladder cancer. The decision is based on results from the pivotal Phase 3 KEYNOTE-B15 study. This is the first PD-1 inhibitor plus antibody drug conjugate regimen cleared for these patients regardless of cisplatin eligibility. The latest approval adds another indication for Merck's flagship oncology drug Keytruda. It reinforces the company’s presence in bladder...